Potent, selective and non toxic c-kit inhibitors

Details Potent, selective and non toxic c-kit inhibitors Potent, selective and non toxic c-kit inhibitors

2002-06-28

2010-06-01

Saunders, David A (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S006120, C435S007240, C435S007800, C435S015000, C435S029000, C435S032000, C435S377000, C436S501000

Reexamination Certificate

active

07727731

ABSTRACT:
The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.

REFERENCES:
patent: 3467666 (1969-09-01), Dexter et al.
patent: 3558653 (1971-01-01), Coyne et al.
patent: 3725403 (1973-04-01), Krapcho
patent: 4587342 (1986-05-01), Daluge et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5639757 (1997-06-01), Dow et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5916769 (1999-06-01), Olsen et al.
patent: 5952374 (1999-09-01), Clarkson
patent: 6114371 (2000-09-01), Tang et al.
patent: 6133305 (2000-10-01), Tang et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6498165 (2002-12-01), Armstrong et al.
patent: 6498176 (2002-12-01), Lackey et al.
patent: 6544988 (2003-04-01), Bilodeau et al.
patent: 6762180 (2004-07-01), Roth et al.
patent: 6958335 (2005-10-01), Buchdunger et al.
patent: 2002/0010203 (2002-01-01), Lipson et al.
patent: 2002/0052386 (2002-05-01), Armistead et al.
patent: 2003/0045451 (2003-03-01), Bacus
patent: 2003/0091974 (2003-05-01), Moussy et al.
patent: 2003/0176443 (2003-09-01), Stein-Gerlach et al.
patent: 2004/0028673 (2004-02-01), Netzer et al.
patent: 2004/0110810 (2004-06-01), Ciufolini et al.
patent: 2004/0241226 (2004-12-01), Moussy et al.
patent: 2004/0242601 (2004-12-01), Moussy et al.
patent: 2004/0242612 (2004-12-01), Moussy et al.
patent: 2004/0259892 (2004-12-01), Moussy et al.
patent: 2004/0259893 (2004-12-01), Moussy et al.
patent: 2004/0266771 (2004-12-01), Moussy et al.
patent: 2004/0266797 (2004-12-01), Moussy et al.
patent: 2004/0266801 (2004-12-01), Moussy et al.
patent: 2005/0054617 (2005-03-01), Moussy et al.
patent: 2005/0059688 (2005-03-01), Moussy et al.
patent: 2005/0089838 (2005-04-01), Moussy et al.
patent: 2005/0176687 (2005-08-01), Moussy et al.
patent: 2005/0222091 (2005-10-01), Moussy et al.
patent: 2006/0166281 (2006-07-01), Moussy et al.
patent: 2006/0204459 (2006-09-01), Moussy et al.
patent: 2006/0275769 (2006-12-01), Moses et al.
patent: 198 24 922 (1999-12-01), None
patent: 198 44 003 (2000-03-01), None
patent: 0 403 238 (1990-12-01), None
patent: 0 564 409 (1993-10-01), None
patent: 0 586 020 (1994-03-01), None
patent: WO 98 18782 (1998-05-01), None
patent: WO 98 35056 (1998-08-01), None
patent: WO 98 41525 (1998-09-01), None
patent: WO 98 50356 (1998-11-01), None
patent: WO 98/55152 (1998-12-01), None
patent: WO 99/03854 (1999-01-01), None
patent: WO 99 61028 (1999-02-01), None
patent: WO 99 11643 (1999-03-01), None
patent: WO 99 15500 (1999-04-01), None
patent: WO 99 21859 (1999-05-01), None
patent: WO 99 61422 (1999-12-01), None
patent: WO 99 65908 (1999-12-01), None
patent: WO 00 09098 (2000-02-01), None
patent: WO 00 40971 (2000-07-01), None
patent: WO 00 55139 (2000-09-01), None
patent: WO 00 56709 (2000-09-01), None
patent: WO 00 67794 (2000-11-01), None
patent: WO 00 73297 (2000-12-01), None
patent: WO 01 16130 (2001-03-01), None
patent: WO 01/27081 (2001-04-01), None
patent: WO 01 45689 (2001-06-01), None
patent: WO 01 47517 (2001-07-01), None
patent: WO 01 47950 (2001-07-01), None
patent: WO 01 49287 (2001-07-01), None
patent: 0164200 (2001-09-01), None
patent: 0164674 (2001-09-01), None
patent: WO 01 90104 (2001-11-01), None
patent: WO 02 40486 (2002-05-01), None
patent: WO 02 55517 (2002-07-01), None
patent: WO 02 072578 (2002-09-01), None
patent: 02080925 (2002-10-01), None
patent: WO 03 002106 (2003-01-01), None
patent: WO 03 035049 (2003-05-01), None
patent: WO 03 035050 (2003-05-01), None
patent: 03062215 (2003-07-01), None
Ma, et al., “Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells”, Journal of Investigative Dermatology, Feb. 2000, pp. 392-394, vol. 114, No. 2.
Imokawa, G. “Paracrine cytokine mechanisms of epidermal hyperpigmentation in UVB-melanosis, lentigo senilis and dematofibroma,”,Pigment Cell Research, 2002, p. 34, vol. 15 Supp. 9.
James M. Grichnik, et al., “The SCF/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis,”The Journal of Investigative Dermatology, vol. 111, No. 2, pp. 233-238, Aug. 1998, XP001133837.
Hattori, H. et al., “The role of the epidermal stem cell factor (SCF)/c-kit cascade in the hyperpigmentation mechanism of lentigo senilis (LS),”Pigment Cell Research, 2002, p. 58, vol. 15, Supp. 9.
A. D. Laird et al, “SU668 Is a Potent Antiangiogenic and Antitumor Agent that Induces Regression of Established Tumors”,Cancer Research, vol. 60, pp. 4152-4160, 2000.
B. Smolich et al, “The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts”,Blood, vol. 97, No. 5, pp. 1413-1421, 2001, XP002229742.
Sinha et al., “Implications for Src Kinases in Hematopoiesis: Signal Transduction Therapeutics”,Journal of Hematotherapy&Stem Cell Research, vol. 8, pp. 465-480, 1999.
Sinha and Corey,Signal Transduction Therapeutics, pp. 471-480, 1999.
Asthma and Bone Health,NIHORBD-NRC Fact Sheets, 4 pages, Dec. 2005.
J. Lesinski, “Preventing Bone Loss”, The Connection Newspapers, pp. 1-2, May 28, 2003.
www.hopkinsmedicine.org, Bone Loss from Chemotherapy,Journal of Clinical Oncology, vol. 19(14); pp. 3306-3311, 2001.
Dolan et al., Rheumatology 41, www.rheumatology.oxfordjournals.org, pp. 1047-1051, 2002.
NIH Osteoporosis and Related Bone Diseases-National Resource Center, “What People With Inflammatory Bowel Disease Need to Know About Osteoporosis”, pp. 1-4, updated Feb. 2005.
Krystal G W, et al., “Indolonone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells”, vol. 61, No. 9, May 1, 2001, pp. 3660-3668.
Moosa, Mohammadi et al, “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors”,Science, vol. 276, No. 5314, pp. 955-960, 1997.
Defazio, et al., “Interferon β-1a downregulates TNF α-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway”,Brain research, vol. 881 (2): pp. 227-230, 2000.
J. Topaly, et al., Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells,Leukemia, vol. 15, pp. 342-347, 2001.
www.gsdl.com, “Laboratory Assessments: IBD and Allergies,” GSDL Inflammatory Bowel Disease (IBD) and Allergies, 2 pages, Dec. 2005.
www.health.ucsd.edu, “Researchers Show Beneficial Role of Bacterial DNA in Fighting Inflammatory Bowel Disease,” UCSD School of Medicine News Health Sciences Communications, 2 pages, Apr. 2002.
J. Jahnsen, et al., “Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study”, Scand. J. Gastroenterol. Feb. 2004; 39(2), abstract only.
H. Mielants, et al., “Course of gut inflammation in spondylarthropathies and therapeutic consequences,” Bailliers Clin. Rheumatol. Feb. 1996; 10(1): abstract only.
A. Yamataka, et al., Localization of Intestinal Pacemaker Cells and Synapses in the Muscle Layers of a Patient with Colonic Hypoganglionosis,Journal of Pediatric Surgery, vol. 31, No. 4, pp. 584-587, 1996.
A. Yamataka, et al., A Lack of Intestinal Pacemaker (c-kit) in Aganalionic Bowel of Patients with Hirschsprung's Disease,Journal of Pediatric Surgery, vol. 30, No. 3, pp. 441-444, 1995.
R. Hicks, “Rheumatoid Arthritis”, www.bbc.co.uk, 2 pages, D

Affiliated with

Also associated with

Rating

Potent, selective and non toxic c-kit inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potent, selective and non toxic c-kit inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potent, selective and non toxic c-kit inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245287